Northside Capital Management LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 22.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,977 shares of the company’s stock after selling 2,299 shares during the period. Northside Capital Management LLC’s holdings in Johnson & Johnson were worth $1,409,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Lincoln Capital Corp lifted its stake in shares of Johnson & Johnson by 15.9% in the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after acquiring an additional 183 shares during the period. Ieq Capital LLC lifted its position in shares of Johnson & Johnson by 5.1% in the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after purchasing an additional 6,154 shares during the period. RFG Advisory LLC boosted its stake in shares of Johnson & Johnson by 2.7% in the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after purchasing an additional 594 shares during the last quarter. FDx Advisors Inc. increased its position in shares of Johnson & Johnson by 0.3% during the third quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock worth $8,237,000 after buying an additional 153 shares during the period. Finally, HM Payson & Co. raised its stake in Johnson & Johnson by 3.2% during the third quarter. HM Payson & Co. now owns 783,538 shares of the company’s stock worth $127,999,000 after buying an additional 24,188 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.35% of the stock is currently owned by corporate insiders.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. During the same quarter last year, the company earned $2.13 earnings per share. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. As a group, research analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were given a dividend of $1.13 per share. The ex-dividend date was Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.99%. Johnson & Johnson’s dividend payout ratio is currently 67.06%.
Wall Street Analyst Weigh In
A number of analysts have weighed in on JNJ shares. Guggenheim started coverage on Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. Citigroup raised their target price on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. StockNews.com started coverage on Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating on the stock. Atlantic Securities raised their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. Finally, SVB Leerink cut their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $174.73.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- KB Home Strong Results Lift Prices
- Chewy Stock Is Setting Up For Long-Term Profitable Growth
- Why Wall Street Loves These 3 Penny Stocks
- Low Volume Bunge Plunge Presents an Opportunity
- Carvana May Be Able To Reach Profitability This Year
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
